Argentina Cancer Drug Market Overview, 2031

Argentina’s oncology market has been evolving under the dual pressures of a rising cancer burden and healthcare system constraints. The country records over 130,000 new cancer cases annually, with breast, prostate, lung, colorectal, and stomach cancers among the most prevalent. An aging population, urbanization, and lifestyle changes—particularly in diet and smoking habits—have contributed to the increasing incidence of malignancies. Public hospitals, which serve the majority of the population, face operational pressures due to limited resources, infrastructure, and oncology specialists, while private hospitals and oncology centers are better equipped to adopt modern therapies. National programs, such as the National Cancer Control Program (Programa Nacional de Control de Cáncer), emphasize early detection, screening, and integration of new therapies into treatment protocols, creating an environment conducive to modernization. Argentina has also seen the gradual adoption of molecular diagnostics and biomarker-driven precision medicine, particularly in breast and lung cancers, allowing targeted and immunotherapy regimens to become more widely available in urban tertiary hospitals. Participation in international clinical trials further accelerates access to innovative therapies, particularly for rare or advanced cancers. Operational constraints, including infusion unit availability, drug supply logistics, and regional disparities between Buenos Aires, Córdoba, and remote provinces, impact adoption. While chemotherapy remains dominant due to cost considerations, targeted therapies, immunotherapies, and biologics are increasingly integrated into public and private treatment regimens. Government reimbursement policies, insurance coverage, and patient assistance programs influence access, creating a dual-tier adoption scenario: urban centers lead in advanced therapy adoption, while public hospitals focus on conventional, high-volume treatments. These factors combine to make Argentina’s oncology drug market a dynamic landscape, balancing cost-effective treatment with gradual integration of innovative therapies and shaping adoption patterns in both public and private healthcare sectors.

According to the research report, "Argentina Cancer Drug Market Outlook, 2031," published by Bonafide Research, the Argentina Cancer Drug market was valued at more than USD 1.93 Billion in 2025. Argentina’s cancer drug supply ecosystem is a mix of domestic manufacturing, multinational imports, and structured distribution networks that support both public and private healthcare providers. Domestic pharmaceutical companies produce generic chemotherapy agents and supportive medications widely used in public hospitals due to cost efficiency, while multinational pharmaceutical firms dominate high-cost innovative therapies such as targeted agents, immunotherapies, and monoclonal antibodies. Supply chains rely heavily on national and regional distributors, which maintain cold-chain compliance and deliver medications to hospitals, oncology centers, and retail pharmacies. Hospital pharmacies act as central hubs, particularly in tertiary hospitals, managing infusion therapies, monitoring complex regimens, and coordinating with manufacturers for timely access to new drugs. After-sales support, including clinical guidance, patient education, and pharmacovigilance, is increasingly considered in vendor selection, especially for biologics and advanced therapies requiring specialized handling. Argentina’s regulatory framework, overseen by the National Administration of Drugs, Foods and Medical Devices (ANMAT), ensures that imported and locally produced oncology drugs meet quality standards, affecting how suppliers structure their operations. Private hospitals often form direct partnerships with pharmaceutical manufacturers to access new treatments faster, while public hospitals depend more on distributors and government procurement channels. Online pharmacies and specialty distributors are gradually emerging, particularly for oral therapies, improving access outside major urban centers. Overall, Argentina’s supply-side ecosystem balances local generics with imported innovative drugs, emphasizing reliable distribution, adherence support, and compliance with regulatory standards to ensure continuity of cancer treatment across diverse regions.

Argentina’s oncology market spans traditional chemotherapy, targeted therapies, immunotherapies, hormonal treatments, and emerging combination regimens. Chemotherapy continues to dominate in public hospitals due to affordability, treating high-incidence cancers such as breast, colorectal, lung, and stomach cancers. Generic chemotherapy drugs form the backbone of high-volume treatments, particularly in rural areas. Targeted therapies are gaining traction in urban centers, supported by biomarker testing and precision medicine protocols, with tyrosine kinase inhibitors and monoclonal antibodies being applied in breast, lung, and hematologic malignancies. Immunotherapies have been progressively integrated, particularly for melanoma, lung cancer, and certain blood cancers, reflecting global clinical trends and improved patient outcomes. Hormonal therapy remains essential for hormone-sensitive cancers like breast and prostate cancer, often in combination with chemotherapy or targeted therapies. Emerging treatments, including antibody-drug conjugates, bispecific antibodies, and cell-based therapies, are primarily adopted in private tertiary hospitals and specialized oncology centers, where the infrastructure supports complex administration and monitoring. The adoption pattern reflects a dual strategy: chemotherapy ensures accessibility and high patient volume coverage, while targeted and immune-based therapies expand selectively among urban and private healthcare facilities. Clinicians weigh treatment efficacy, patient convenience, and hospital capacity when selecting therapy, balancing innovation with operational feasibility. Overall, Argentina’s therapy mix demonstrates gradual modernization alongside traditional approaches, reflecting a healthcare system managing resource constraints while progressively integrating advanced oncology treatments.

Cancer drug demand in Argentina is closely tied to prevalence, disease burden, and treatment infrastructure. Breast cancer represents the largest segment, treated through chemotherapy, hormonal therapy, targeted therapy, and increasingly, immunotherapy, particularly in tertiary hospitals. Lung cancer, including non-small cell and small cell types, drives demand for targeted therapies, immunotherapies, and chemotherapy, particularly in urban centers where molecular profiling is available. Colorectal cancer is commonly detected via screening programs, with treatment relying on chemotherapy and targeted regimens for advanced cases. Prostate cancer management primarily involves hormonal therapy, supplemented by chemotherapy or targeted therapies for advanced stages. Blood cancers, such as leukemia, lymphoma, and multiple myeloma, are treated with immunomodulatory agents, biologics, and combination regimens in specialized centers. Cervical and stomach cancers remain prevalent in certain regions, requiring chemotherapy and emerging targeted therapies. Other cancers, including liver, kidney, ovarian, bladder, brain, thyroid, and skin cancers, contribute to the market, with high-cost therapies concentrated in urban tertiary hospitals. Treatment patterns reflect both prevalence and hospital capacity, with public hospitals focusing on conventional, high-volume chemotherapy while private and urban centers lead in advanced therapy adoption. National clinical guidelines, reimbursement policies, and regional infrastructure further influence therapy allocation, ensuring that high-burden cancers are prioritized while innovative treatments gradually expand to rarer malignancies. This diverse landscape creates a balance between broad accessibility and selective modernization, reflecting Argentina’s evolving oncology ecosystem.

In Argentina, cancer drugs are primarily administered through injectable and oral routes, reflecting clinical needs and patient convenience. Injectable therapies dominate chemotherapy, immunotherapy, and biologics, particularly in tertiary hospitals and private centers equipped with specialized infusion units and trained staff. Intravenous and subcutaneous delivery ensures precise dosing, safety, and efficacy for high-risk or combination regimens, such as those used in breast, lung, colorectal, and hematologic cancers. Oral therapies, including targeted drugs and hormonal treatments, are increasingly used in long-term maintenance therapy and outpatient care, reducing hospital visits and enhancing patient convenience. Patient adherence is monitored through hospital counseling, pharmacy follow-ups, and digital tools, especially for therapies requiring long-term compliance. Combining injectable and oral therapies allows physicians to tailor treatment plans based on cancer type, stage, and patient preference. In rural or semi-urban regions, oral therapies help mitigate logistical challenges associated with repeated hospital visits, while urban centers focus on infusion-based administration for complex regimens. This dual approach reflects Argentina’s commitment to patient-centered care, balancing convenience, safety, and clinical effectiveness, while ensuring equitable access across urban and regional areas.



Argentina’s cancer drug distribution network integrates hospital pharmacies, retail outlets, specialty centers, and emerging digital platforms to provide broad access across the country. Hospital pharmacies are the primary distribution point for injectable therapies, coordinating inventory, dosing schedules, infusion services, and patient monitoring. Public hospitals procure oncology drugs through government tenders and centralized procurement programs, ensuring affordability and consistent supply for large patient populations. Private hospitals and oncology centers often partner directly with manufacturers to access high-cost targeted therapies and immunotherapies quickly. Retail pharmacies and community outlets distribute oral cancer drugs and supportive medications, offering counseling, adherence monitoring, and prescription refills. Specialty distributors and logistics providers maintain cold-chain integrity and ensure timely delivery of temperature-sensitive biologics, particularly in tertiary hospitals and urban centers. Online pharmacies are gradually emerging, enabling home delivery and access to oral therapies in semi-urban and rural regions. After-sales services, including patient support programs, clinical training for healthcare professionals, and pharmacovigilance, are increasingly critical for complex therapies and influence supplier selection. The system balances public accessibility with private sector innovation, ensuring cancer drugs are reliably available nationwide while meeting operational, regulatory, and clinical standards.
Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Cancer Drug Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Therapy Type
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormonal Therapy
• Other Treatment Types
By Indication
• Breast Cancer
• Lung Cancer (Non-Small Cell Lung Cancer and Small Cell Lung Cancer)
• Colorectal Cancer
• Prostate Cancer
• Blood Cancers (Leukemia, Lymphoma, Multiple Myeloma))
• cervical cancer
• Stomach/ Gastric Cancer
• Others (Liver Cancer ,Kidney Cancer (Renal Cell Carcinoma) , ovarian Cancer, Bladder Cancer, Skin Cancer, Brain tumor, Thyroid Cancer )
By Route of Administration
• Oral
• Injectable
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies / Drug Stores
• Online Pharmacies